Evidence map›Paper›PMID 30171178›Full record

ArticleMedical science monitor : international medical journal of experimental and clinical research2018

Clinical Significance of Serum lncRNA Cancer Susceptibility Candidate 2 (CASC2) for Chronic Renal Failure in Patients with Type 2 Diabetes.

Linxia Wang, Na Su, Yunna Zhang, Guangya Wang

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Medical science monitor : international medical journal of experimental and clinical research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 4 pooled it
1.7field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 4 syntheses or guidelines pooled it, 34 citations in OpenAlex.

  1. Pooled it
  2. Epigenetic Mechanisms in Type 2 Diabetes Retinopathy: A Systematic Review.International journal of molecular sciences · 2021
    Pooled it
  3. Pooled it
  4. Pooled it
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Urinary Long Non-Coding RNA Levels as Biomarkers of Lupus Nephritis.International journal of molecular sciences · 2023
    Article
  12. Long non-coding RNAs: a valuable biomarker for metabolic syndrome.Molecular genetics and genomics : MGG · 2022
    Review
  13. Review
  14. Review
  15. Article
  16. Non-Coding RNAs: Novel Players in Insulin Resistance and Related Diseases.International journal of molecular sciences · 2021
    Review
  17. Role of long non-coding RNAs in adipogenesis: State of the art and implications in obesity and obesity-associated diseases.Obesity reviews : an official journal of the International Association for the Study of Obesity · 2021
    Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Linxia Wang2nd Department of Endocrinology, Cangzhou Central Hospital, Cangzhou, Hebei, China (mainland).
Na Su2nd Department of Endocrinology, Cangzhou Central Hospital, Cangzhou, Hebei, China (mainland).
Yunna Zhang2nd Department of Endocrinology, Cangzhou Central Hospital, Cangzhou, Hebei, China (mainland).
Guangya Wang2nd Department of Endocrinology, Cangzhou Central Hospital, Cangzhou, Hebei, China (mainland).
Cangzhou Central Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND LncRNA CASC2 has been established to have critical functions in tumorigenesis but, while its involvement in high-glucose-induced chronic renal failure remains unclear. MATERIAL AND METHODS We included patients with type 2 diabetes combined with chronic renal failure, as well as patients with diabetic retinopathy, diabetic ketoacidosis, diabetic foot infections or diabetic cardiomyopathy, and diabetic patients without any obvious complication, as well as healthy controls. Blood samples and renal tissues were obtained from each participant and expression of lncRNA CASC2 in those tissues was detected by qRT-PCR. Diagnostic value of lncRNA CASC2 for type 2 diabetes combined with chronic renal failure was evaluated by ROC curve analysis. All patients were followed up for 5 years and the occurrence of chronic renal failure was recorded. RESULTS Compared with healthy controls, expression of lncRNA CASC2 in serum and renal tissue was specifically downregulated in patients with type 2 diabetes combined with chronic renal failure but not in type 2 diabetic patients combined with other complications. Follow-up showed that patients with low serum level of lncRNA CASC2 had significantly higher incidence of chronic renal failure. CONCLUSIONS lncRNA CASC2 is a reliable diagnostic biomarker for type 2 diabetes combined with chronic renal failure and low serum level of lncRNA CASC2 predicts the occurrence of chronic renal failure in patients with type 2 diabetes.

Indexed as

AdultAgedCase-Control StudiesCell ProliferationDiabetes Mellitus, Type 2Diabetic NephropathiesDown-RegulationFemaleHumansKidney Failure, ChronicMaleMiddle AgedRenal Insufficiency, ChronicRNA, Long NoncodingTumor Suppressor Proteinslong non-coding RNA CASC2, humanRNA, Long NoncodingTumor Suppressor Proteins

Identifiers

PMID30171178
PMCPMC6130171
OpenAlexW2889481842

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.